COMMUNIQUÉS West-GlobeNewswire

Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin
17/02/2026
HOUSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that the Japan Patent Office (JPO) has issued a notice of allowance for Patent [...]
Vivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production Sites
17/02/2026
Kennewick, WA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering its innovative RadioGel ® Radionuclide Therapy ™ (PRnT ™ ) is preparing to open two new production [...]
ViroMissile Expands Phase I IDOV-ImmuneTM Trial to U.S. Sites Following IND Clearance
17/02/2026
SAN DIEGO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- ViroMissile , Inc., a cancer immunotherapy company pioneering the IDOV™ (Intravenously Deliverable Oncolytic Virus) platform, today announced the expansion of its ongoing [...]
Sienna Continues Platform Growth in Ontario and British Columbia
17/02/2026
MARKHAM, Ontario, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (" Sienna " or the " Company ") (TSX: SIA) announced today that it has entered into a purchase agreement to acquire a retirement residence in [...]
Earth Science Tech, Inc. (ETST) Reports Third Fiscal Quarter 2026 Results
17/02/2026
Revenue of $8.4 million, up 14.1% year-over-year Gross profit margin of 76.3%, up 71 bps year-over-year Net income of $910,000, up 341% year-over-year Generated positive cash from operations of $1.2 million fiscal year- [...]
Integra LifeSciences Announces Key Executive Leadership Appointments
17/02/2026
Executive team further strengthened with appointments of Teshtar Elavia to the newly created chief technology officer role, Michael Hutchinson as chief legal officer, and Kerri DiPietro as chief quality officer, [...]
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
17/02/2026
AUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage : Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage [...]
Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial
17/02/2026
PARAMUS, NJ, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage [...]
STRATA Skin Sciences Highlights Meta-Analysis Confirming Clinical Efficacy of 308 nm Excimer Laser for Plaque Psoriasis
17/02/2026
Growing body of clinical data like February 2026 publication from Georgetown University supports optimized, targeted Excimer laser UVB strategies for inflammatory skin conditions HORSHAM, Pa., Feb. 17, 2026 (GLOBE [...]
Nanox to Showcase Nanox.ARC Live in Europe for First Time and Present New AI Capabilities at ECR 2026
17/02/2026
Live demonstrations of the Nanox.ARC will feature at the ECR booth #425 in Hall X4 Oral presentation by Dr. Nogah Shabshin to present data on potential role of digital tomosynthesis in lung cancer screening Oral [...]
BillionToOne to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
17/02/2026
MENLO PARK, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, [...]
Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
17/02/2026
Continued expansion of LYTENAVA™ (bevacizumab gamma) in Europe underway, including commercial launch in Austria in January 2026 Additional European launches expected in 2026 Type A meeting request submitted to the U.S. [...]
Cellectar Biosciences Expands Global Intellectual Property Estate
17/02/2026
Strengthens Protection Around Broad Portfolio of Cancer-Targeting Drug Conjugates and Enabling Technologies Provides Key Coverage Across Europe Ahead of Planned 3Q26 Filing for Conditional Marketing Approval with the [...]
Extendicare Announces February 2026 Dividend of C$0.042 per Share
17/02/2026
MARKHAM, Ontario, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.042 per common share of the Company for the month of [...]
Lifeward’s ReWalk™ Personal Exoskeleton Now Covered by Aetna, Coverage Expands to Include Three of the Largest Medicare Advantage Insurers
17/02/2026
Aetna joins Humana and United Healthcare in providing Medicare Advantage coverage for beneficiaries who meet medical necessity criteria for the ReWalk Personal Exoskeleton Together, these three national Medicare [...]
MIMEDX to Host Fourth Quarter and Full Year 2025 Operating and Financial Results Conference Call on February 25
17/02/2026
MARIETTA, Ga., Feb. 17, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the fourth quarter and full year [...]
Prenetics Completes $70 Million Insighta Sale to Tencent, Bolstering Balance Sheet to $171.1 Million in Total Adjusted Liquidity
17/02/2026
Final Milestone in Strategic Transformation Positions Company to Accelerate IM8 Global Expansion with Zero Debt Q4 and Full-Year 2025 Financial Results to be Announced Pre-Market on February 18, 2026 NEW YORK, Feb. 17, [...]
Casey House releases Big Fucking Deal, a short film examining the compounding effects of stigma for people living with HIV
17/02/2026
Study reveals only 44% of Canadians are confident that people living with HIV receive stigma-free health care when they need it – a gap the film recognizes through storytelling TORONTO, Feb. 17, 2026 (GLOBE NEWSWIRE [...]
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
17/02/2026
SUMMIT NDA for bezuclastinib in patients with NonAdvSM submitted in December 2025; APEX NDA submission for bezuclastinib in patients with AdvSM on track for 1H 2026 PEAK NDA initiated for bezuclastinib in patients with [...]

Pages